EMA/35874/2023

European Medicines Agency decision

P/0047/2023

of 24 January 2023

on the acceptance of a modification of an agreed paediatric investigation plan for enmetazobactam (AAI101) / cefepime (EMEA-002240-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0047/2023

of 24 January 2023

on the acceptance of a modification of an agreed paediatric investigation plan for enmetazobactam (AAI101) / cefepime (EMEA-002240-PIP02-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0093/2019 issued on 22 March 2019 and the decision P/0340/2022 issued on 10 August 2022,

Having regard to the application submitted by Allecra Therapeutics GmbH on 24 November 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 January 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for enmetazobactam (AAI101) / cefepime, powder for concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Allecra Therapeutics GmbH, c/o Loeba Treuhand GmbH – 24 Wallbrunnstrasse, 79539 – Lörrach, Germany.

EMA/PDCO/907270/2022
Amsterdam, 20 January 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002240-PIP02-17-M02

Scope of the application

Active substance(s):

Enmetazobactam (AAI101) / Cefepime

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of infections caused by gram-negative organisms

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Allecra Therapeutics GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Allecra Therapeutics GmbH submitted to the European Medicines Agency on 24 November 2022 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0093/2019 issued on 22 March 2019 and the decision P/0340/2022 issued on 10 August 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2023.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Amendment of the pharmaceutical form and amendment of the scope of the Paediatric Investigation Plan to update the condition.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of infections caused by gram-negative organisms

2.1.1. Indication(s) targeted by the PIP

Treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis

Treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).

Treatment of patients with bacteraemia that occurs in association with or is suspected to be associated with any of the above infections.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of age-appropriate dosage formulation(s) for parenteral use of fixed dose combination (FDC) of cefepime and enmetazobactam at a ratio to be determined based on study 5 in paediatric subjects from birth to less than 18 years of age.
Non-clinical studies	**Study 2** Definitive juvenile toxicity study in rats at a developmental age of 10 days via subcutaneous administration. **Study 3** Definitive juvenile toxicity study in rats at a developmental age of 21 days via intravenous administration.
Clinical studies	**Study 4** Open-label, multi-dose study to assess the pharmacokinetics, safety and tolerability of cefepime/enmetazobactam in paediatric subjects from birth to less than 18 years of age with suspected or confirmed complicated urinary infections (cUTI)

Extrapolation, modelling and simulation studies	**Study 5** Modelling and simulation study to evaluate the use of cefepime and enmetazobactam for the treatment of paediatric subjects from birth to less than 18 years of age with certain infections caused by Gram-negative bacteria. **Study 6** Extrapolation study to evaluate the use of cefepime and enmetazobactam for the treatment of paediatric subjects from birth to less than 18 years of age with certain infections caused by Gram-negative bacteria.
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.